Department of Pharmacology and Clinical Pharmacy, Faculty of Pharmacy, Al-Fateh Medical University, Tripoli, Libya.
Libyan J Med. 2010 Jun 21;5. doi: 10.3402/ljm.v5i0.5303.
Allergic asthma is a disease characterized by persistent allergen-driven airway inflammation, remodeling, and airway hyperresponsiveness. CD4(+) T-cells, especially T-helper type 2 cells, play a critical role in orchestrating the disease process through the release of the cytokines IL-4, IL-5, and IL-13. Allergen-specific immunotherapy (SIT) is currently the only treatment with a long-term effect via modifying the natural course of allergy by interfering with the underlying immunological mechanisms. However, although SIT is effective in allergic rhinitis and insect venom allergy, in allergic asthma it seldom results in complete alleviation of the symptoms. Improvement of SIT is needed to enhance its efficacy in asthmatic patients. Herein, the immunoregulatory mechanisms underlying the beneficial effects of SIT are discussed with the ultimate aim to improve its treatment efficacy.
变应性哮喘是一种以持续性过敏原驱动的气道炎症、重塑和气道高反应性为特征的疾病。CD4+T 细胞，特别是辅助性 T 细胞 2 型，通过释放细胞因子 IL-4、IL-5 和 IL-13，在协调疾病过程中发挥关键作用。变应原特异性免疫疗法（SIT）是目前唯一通过干扰潜在免疫机制来改变过敏自然进程的具有长期疗效的治疗方法。然而，尽管 SIT 在过敏性鼻炎和昆虫毒液过敏中有效，但在变应性哮喘中，它很少能完全缓解症状。需要改进 SIT 以提高其在哮喘患者中的疗效。本文讨论了 SIT 有益作用的免疫调节机制，最终目的是提高其治疗效果。
